Novel blood cancer drug developed by Alembic Pharma#39;s associate Rhizen gets US approval

Novel blood cancer drug developed by Alembic Pharma#39;s associate Rhizen gets US approval Umbralisib has peak market size potential to reach $1 billion - $1.5 billion

No comments:

Post a Comment